Anixa Biosciences, Inc. (ANIX): Business Model Canvas [Jan-2025 Updated]

Anixa Biosciences, Inc. (ANIX) stands at the forefront of revolutionary cancer research, transforming the landscape of diagnostic and therapeutic technologies with its cutting-edge approach. By leveraging strategic partnerships, innovative research methodologies, and breakthrough scientific platforms, the company is pioneering non-invasive detection and potential treatment solutions for complex cancer types like ovarian and breast cancer. Their unique business model intertwines scientific innovation, collaborative research, and advanced medical technology to create transformative healthcare solutions that could potentially redefine cancer diagnostics and treatment.

Anixa Biosciences, Inc. (ANIX) - Business Model: Key Partnerships

Strategic Collaboration with Cleveland Clinic

Anixa Biosciences has an ongoing strategic collaboration with Cleveland Clinic focused on cancer diagnostic technology development. The partnership involves joint research efforts in innovative cancer detection methods.

Partnership Detail	Specifics
Collaboration Start Date	2018
Research Focus	Cancer diagnostic technology
Collaboration Type	Research and technology development

Research Partnerships with Academic Medical Institutions

Anixa maintains collaborative relationships with multiple academic medical research institutions to advance its scientific research initiatives.

• University of Miami
• Moffitt Cancer Center
• Other undisclosed academic research partners

Potential Pharmaceutical and Biotechnology Alliance Partners

Anixa is actively exploring potential strategic alliances with pharmaceutical and biotechnology companies to advance its therapeutic and diagnostic technologies.

Potential Partner Category	Focus Areas
Oncology-focused Pharmaceutical Companies	Cancer therapeutics development
Biotechnology Research Firms	Diagnostic technology collaboration

Collaborative Agreements with Technology Transfer Offices

Anixa engages with technology transfer offices to identify and commercialize innovative medical research technologies.

• Technology transfer agreements with research institutions
• Intellectual property licensing negotiations
• Collaborative technology development frameworks

Anixa Biosciences, Inc. (ANIX) - Business Model: Key Activities

Developing Innovative Cancer Diagnostic Technologies

As of Q4 2023, Anixa Biosciences focused on developing CAR-T immunotherapy technologies and cancer diagnostic platforms.

Technology Area	Research Focus	Patent Status
CAR-T Immunotherapy	Ovarian and Triple Negative Breast Cancer	Multiple Pending Patents
Cancer Diagnostic Platform	Early Detection Technologies	3 Active Patent Applications

Conducting Preclinical and Clinical Research

Research expenditure for 2023 totaled $4.2 million, dedicated to advancing therapeutic platforms.

• Preclinical studies for CAR-T therapeutic approaches
• Clinical research collaborations with academic institutions
• Ongoing investigational programs in cancer immunotherapy

Pursuing Patent Development and Intellectual Property Protection

As of December 2023, Anixa held 7 active patent families.

Patent Category	Number of Patents	Estimated Value
CAR-T Technology	4	$3.5 million
Diagnostic Platform	3	$2.1 million

Performing Translational Medicine Research

Research investment in translational medicine reached $2.8 million in 2023.

• Collaboration with Mayo Clinic for research translation
• Focus on converting laboratory discoveries into clinical applications
• Developing therapeutic strategies for challenging cancer types

Advancing Therapeutic and Diagnostic Platforms

R&D budget allocation for platform advancement was $6.5 million in fiscal year 2023.

Platform	Development Stage	Potential Market Impact
CAR-T Immunotherapy	Phase I/II Clinical Trials	Potential $50-100 million market opportunity
Cancer Diagnostic Technology	Pre-clinical Development	Estimated $30-75 million potential market

Anixa Biosciences, Inc. (ANIX) - Business Model: Key Resources

Proprietary Cancer Detection and Treatment Technologies

As of Q4 2023, Anixa Biosciences holds 3 primary technology platforms in cancer detection and treatment:

Technology Platform	Specific Focus	Patent Status
CAR-T Platform	Ovarian Cancer Treatment	2 Active Patent Applications
Breast Cancer Vaccine	Preventative Immunotherapy	1 Provisional Patent
Cancer Detection Technology	Early Stage Diagnostic Method	1 Pending Patent

Specialized Scientific and Research Personnel

Research workforce composition as of 2024:

• Total Research Staff: 18 employees
• PhD Holders: 12
• MD Researchers: 3
• Research Specialties: Immunology, Oncology, Molecular Biology

Intellectual Property Portfolio

IP Category	Total Count	Active/Pending Status
Patent Applications	6	4 Active, 2 Pending
Provisional Patents	2	Both Active

Research and Development Infrastructure

R&D Investment Metrics for 2023:

• Total R&D Expenditure: $8.3 million
• R&D as Percentage of Revenue: 72%
• Research Facilities: 2 Collaborative Laboratory Spaces

Access to Advanced Medical Research Facilities

Research Collaboration	Institution Type	Research Focus
Cleveland Clinic	Academic Medical Center	Breast Cancer Vaccine Development
Moffitt Cancer Center	Comprehensive Cancer Center	CAR-T Technology Validation

Anixa Biosciences, Inc. (ANIX) - Business Model: Value Propositions

Innovative Cancer Diagnostic and Therapeutic Solutions

Anixa Biosciences focuses on developing advanced cancer technologies with specific value propositions:

Technology Category	Specific Focus	Development Stage
Cancer Diagnostics	Early detection technologies	Preclinical/Clinical Development
Cancer Therapeutics	Immunotherapy platforms	Experimental Research

Early Detection Technologies for Challenging Cancer Types

Anixa's key diagnostic value propositions include:

• Ovarian cancer early detection platform
• Non-invasive screening methodologies
• Proprietary biomarker identification technologies

Potential Breakthrough Treatments for Ovarian and Breast Cancer

Cancer Type	Technology Approach	Patent Status
Ovarian Cancer	CAR-T Cell Therapy	Multiple Patent Applications
Breast Cancer	Immunotherapy Platform	Provisional Patent Protection

Non-Invasive Diagnostic Approaches

Anixa's diagnostic strategies emphasize:

• Minimal patient discomfort
• High precision screening methods
• Cost-effective testing protocols

Personalized Medical Technology Platforms

Key personalization technologies include:

Technology Platform	Customization Level	Potential Impact
Cancer Immunotherapy	Patient-Specific Targeting	Precision Treatment Approach
Diagnostic Screening	Individual Risk Assessment	Personalized Prevention Strategy

Anixa Biosciences, Inc. (ANIX) - Business Model: Customer Relationships

Direct Engagement with Medical Research Institutions

As of Q4 2023, Anixa Biosciences maintains direct research collaborations with the following institutions:

Institution	Collaboration Focus	Established Year
Cleveland Clinic	Cancer Immunotherapy Research	2018
Moffitt Cancer Center	Breast Cancer Vaccine Development	2021

Collaborative Research Partnerships

Current active research partnerships include:

• Collaboration with Cleveland Clinic on CAR-T technology
• Breast cancer vaccine development partnership
• Immuno-oncology research agreements

Scientific Conference and Industry Event Interactions

Annual scientific conference participation data for 2023:

Conference	Presentations	Networking Meetings
ASCO Annual Meeting	2	12
AACR Annual Meeting	1	8

Transparent Communication of Research Progress

Communication channels for research updates:

• Quarterly earnings calls
• Press releases
• SEC filings
• Company website research updates

Investor and Stakeholder Communication Channels

Investor communication metrics for 2023:

Channel	Frequency	Reach
Investor Conferences	4 per year	150+ institutional investors
Earnings Webinars	Quarterly	250+ participants

Anixa Biosciences, Inc. (ANIX) - Business Model: Channels

Scientific Publications and Peer-Reviewed Journals

Anixa Biosciences utilizes 7 primary peer-reviewed journals for channel communication in 2024:

Journal Name	Publication Frequency	Impact Factor
Nature Biotechnology	Monthly	41.4
Cancer Research	24 issues/year	12.3
Journal of Immunology	24 issues/year	4.7

Medical and Biotechnology Conferences

Conference participation channels in 2024:

• American Association for Cancer Research Annual Meeting
• ASCO Annual Meeting
• World Vaccine Congress

Direct Sales to Research Institutions

Institutional sales breakdown for 2024:

Institution Type	Number of Institutions	Annual Sales Volume
University Research Centers	42	$3.2 million
Private Research Laboratories	18	$1.7 million

Online Investor Relations Platforms

Digital investor engagement channels:

• NASDAQ Investor Relations Website
• SEC EDGAR Filing Platform
• Company Investor Relations Webpage

Academic and Medical Network Presentations

Presentation channel metrics for 2024:

Presentation Type	Number of Presentations	Estimated Audience Reach
Virtual Webinars	12	3,500 professionals
In-Person Symposiums	6	1,200 researchers

Anixa Biosciences, Inc. (ANIX) - Business Model: Customer Segments

Academic Medical Research Centers

As of 2024, Anixa Biosciences targets approximately 150 top-tier academic medical research centers in the United States.

Research Center Type	Number of Potential Customers	Annual Research Budget Range
Comprehensive Cancer Centers	52	$10M - $250M
NCI-Designated Centers	71	$5M - $150M

Oncology Research Institutions

Anixa focuses on specialized oncology research institutions worldwide.

• Global oncology research institutions: 287
• Potential target institutions: 112
• Annual research spending: $3.2 billion

Pharmaceutical Companies

Target pharmaceutical companies with oncology research interests.

Company Category	Number of Potential Customers	Annual R&D Budget
Large Pharmaceutical Companies	20	$5B - $15B
Mid-size Pharmaceutical Companies	45	$500M - $2B

Biotechnology Firms

Focused on biotechnology firms specializing in cancer research and immunotherapy.

• Total biotechnology firms globally: 4,500
• Potential target firms: 276
• Annual biotechnology R&D spending: $79.6 billion

Healthcare Technology Investors

Target investors interested in innovative cancer research technologies.

Investor Type	Number of Potential Investors	Average Investment Range
Venture Capital Firms	89	$2M - $50M
Private Equity Investors	42	$10M - $100M

Anixa Biosciences, Inc. (ANIX) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Anixa Biosciences reported R&D expenses of $8.34 million.

Fiscal Year	R&D Expenses
2023	$8.34 million
2022	$6.92 million

Clinical Trial Investments

Clinical trial investments for Anixa Biosciences in 2023 were approximately $4.5 million.

Intellectual Property Registration and Maintenance

Annual intellectual property costs for Anixa Biosciences were estimated at $250,000.

Personnel and Scientific Talent Compensation

Personnel Category	Annual Compensation
Executive Compensation	$1.2 million
Scientific Staff	$3.6 million

Technology Development and Infrastructure Costs

• Laboratory Equipment: $1.5 million
• Software and Technology Infrastructure: $750,000
• Facility Maintenance: $600,000

Total Operational Cost Structure for 2023: Approximately $16.94 million

Anixa Biosciences, Inc. (ANIX) - Business Model: Revenue Streams

Potential Licensing of Diagnostic Technologies

As of Q4 2023, Anixa Biosciences has potential revenue streams from diagnostic technology licensing. The company's specific licensing revenue for 2023 was $0 based on their annual financial reports.

Research Grants and Government Funding

Funding Source	Amount	Year
National Institutes of Health (NIH) Grants	$325,000	2023
Department of Defense Research Funding	$250,000	2023

Collaborative Research Agreements

Anixa Biosciences has collaborative research agreements with multiple institutions. Total collaborative research revenue for 2023 was approximately $475,000.

Future Therapeutic Technology Commercialization

• Potential cancer immunotherapy technology development
• Estimated potential market value: $50-100 million
• No current commercial revenue from therapeutic technologies

Potential Milestone and Royalty Payments

Technology Area	Potential Milestone Payment Range	Potential Royalty Percentage
CAR-T Cancer Therapy	$1-5 million	3-7%
Diagnostic Technologies	$500,000-$2 million	2-5%

Total revenue for Anixa Biosciences in 2023 was $1,050,000, primarily from research grants and collaborative agreements.